Abstract
Introduction: The incidence of type 1 diabetes (T1D) is increasing worldwide and there is a very large need for effective therapies. Essentially no therapies other than insulin are currently approved for the treatment of T1D. Drugs already in use for type 2 diabetes and many new drugs are under clinical development for T1D, including compounds with both established and new mechanisms of action.
Content of the Review: Most of the new compounds in clinical development are currently in Phase 1 and 2. Drug classes discussed in this review include new insulins, SGLT inhibitors, GLP-1 agonists, immunomodulatory drugs including autoantigens and anti-cytokines, agents that regenerate β-cells and others. Regulatory Considerations: In addition, considerations are provided with regard to the regulatory environment for the clinical development of drugs for T1D, with a focus on the United States Food and Drug Administration and the European Medicines Agency. Future opportunities, such as combination treatments of immunomodulatory and beta-cell regenerating therapies, are also discussed.Keywords: Type 1 diabetes, new drug development, regulatory environment, FDA, EMA, new mechanisms of action, insulins; anti-inflammatory drugs, immunomodulatory, islet regeneration.
Current Diabetes Reviews
Title:Addressing Unmet Medical Needs in Type 1 Diabetes: A Review of Drugs Under Development
Volume: 13 Issue: 3
Author(s): Friedrich Mittermayer*, Erica Caveney, Claudia De Oliveira, G. Alexander Fleming, Loukas Gourgiotis, Mala Puri, Li-Jung Tai and J. Rick Turner
Affiliation:
- Quintiles GmbH, Stella-Klein-Löw Weg 15, Rund 4, Haus B, OG 4, 1020 Vienna,Austria
Keywords: Type 1 diabetes, new drug development, regulatory environment, FDA, EMA, new mechanisms of action, insulins; anti-inflammatory drugs, immunomodulatory, islet regeneration.
Abstract: Introduction: The incidence of type 1 diabetes (T1D) is increasing worldwide and there is a very large need for effective therapies. Essentially no therapies other than insulin are currently approved for the treatment of T1D. Drugs already in use for type 2 diabetes and many new drugs are under clinical development for T1D, including compounds with both established and new mechanisms of action.
Content of the Review: Most of the new compounds in clinical development are currently in Phase 1 and 2. Drug classes discussed in this review include new insulins, SGLT inhibitors, GLP-1 agonists, immunomodulatory drugs including autoantigens and anti-cytokines, agents that regenerate β-cells and others. Regulatory Considerations: In addition, considerations are provided with regard to the regulatory environment for the clinical development of drugs for T1D, with a focus on the United States Food and Drug Administration and the European Medicines Agency. Future opportunities, such as combination treatments of immunomodulatory and beta-cell regenerating therapies, are also discussed.Export Options
About this article
Cite this article as:
Mittermayer Friedrich*, Caveney Erica, De Oliveira Claudia, Fleming Alexander G., Gourgiotis Loukas, Puri Mala, Tai Li-Jung and Turner Rick J., Addressing Unmet Medical Needs in Type 1 Diabetes: A Review of Drugs Under Development, Current Diabetes Reviews 2017; 13 (3) . https://dx.doi.org/10.2174/1573399812666160413115655
DOI https://dx.doi.org/10.2174/1573399812666160413115655 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
Call for Papers in Thematic Issues
Oxidative and Inflammatory Responses in the Development of Secondary Diabetic Complications
Diabetes, along with its associated secondary complications, represents a significant global health challenge, contributing significantly to morbidity and mortality. Unhealthy lifestyle habits, reduced physical activity, environmental pollutants, and stress are pivotal factors in the onset of diabetes, particularly type-2 diabetes. Poorly managed hyperglycemia can lead to various complications, including neuropathy, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Simultaneous Bilateral Basal Ganglia Hemorrhage
Current Drug Delivery Water Soluble Vitamins and their Role in Diabetes and its Complications
Current Diabetes Reviews Diabetes Exacerbates Nanoparticles Induced Brain Pathology
CNS & Neurological Disorders - Drug Targets Balaglitazone: A Second Generation Peroxisome Proliferator-Activated Receptor (PPAR) Gamma (γ) Agonist
Mini-Reviews in Medicinal Chemistry The Protective Effects of Natural Products on Blood-Brain Barrier Breakdown
Current Medicinal Chemistry More Effective DPP4 Inhibitors as Antidiabetics Based on Sitagliptin Applied QSAR and Clinical Methods
Current Computer-Aided Drug Design Burkholderia mallei and Burkholderia pseudomallei: The Causative Micro-organisms of Glanders and Melioidosis
Recent Patents on Anti-Infective Drug Discovery Anti-HCV Prevalence among Diabetic and Non-Diabetic Egyptian Children
Current Diabetes Reviews Current Issues in Intravenous Fluid Use in Hospitalized Children
Reviews on Recent Clinical Trials SGLT2 Inhibitors and Kidney Diseases: A Clinical Perspective
Current Medicinal Chemistry Non-glycemic Adverse Effects of Insulin
Current Diabetes Reviews Opportunities for Nano-Formulations in Type 2 Diabetes Mellitus Treatments
Current Pharmaceutical Biotechnology Transition of Care for Patients with Diabetes
Current Diabetes Reviews Hyperglycemic Hyperosmolar State: A Pragmatic Approach to Properly Manage Sodium Derangements
Current Diabetes Reviews Individual Case Safety Reports Analysis for Patients with Diabetes Mellitus on Insulin in Africa and the Middle East
Current Drug Safety Computer-Based versus Paper-Based Insulin Infusion Algorithms in Diabetic Ketoacidosis
Current Diabetes Reviews Somatostatin and its Analogs
Current Drug Targets Glycaemic Control in Cardiac Surgery Patients: a Double-Edged Sword
Current Vascular Pharmacology Management of Type-1 and Type-2 Diabetes by Insulin Injections in Diabetology Clinics - A Scientific Research Review
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Proteomic Analysis of Liver Diseases: Molecular Mechanisms and Biomarker Discovery
Mini-Reviews in Medicinal Chemistry